Answer
The injected formulation is a ready-to-use abdominal subcutaneous solution containing hyaluronidase. The intravenous concentrate must be diluted and infused. Their licensed indications are not identical, and administration reactions were less frequent with the subcutaneous formulation in comparative studies.
Sources for this answer
- DARZALEX 1,800 mg solution for injection — Current selected SmPCemc · Summary of Product Characteristics
- DARZALEX 20 mg/mL concentrate for solution for infusion — Current selected SmPC